News & Updates

Early pulmonary hypertension (PH) is highly prevalent among infants born preterm and appears to be related to the development of bronchopulmonary dysplasia (BPD), a recent study has found.

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Women with very high levels of high-density lipoprotein cholesterol (HDL-C) are at heightened risk of cardiovascular mortality, with the association following a J-shaped pattern, as reported in a study. Of note, the risk of cardiovascular mortality increases with concomitant hyperuricaemia.

Use of antipsychotics, particularly long-acting injectables, results in nearly 30‒50-percent reduced risk of work disability among individuals with first-episode nonaffective psychosis compared with nonuse, a study has shown. This benefit persists beyond 5 years after first diagnosis.

First-line treatment with durvalumab plus gemcitabine and cisplatin (GC) leads to improved overall (OS) and progression-free survival (PFS) in advanced biliary tract cancer (BTC) across genomic variants, according to the results of the phase III study TOPAZ-1, presented at the ESMO Asia 2022.

Several barriers and facilitators indicate the need to create work environments where safety is a priority for the handling of antineoplastic drugs, suggests a Canada study.

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.